SCHEMBL1617028 — predicted protein targets

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	MAPK14	Q16539	17/20	0.49

▸	LIMK1	P53667	5/20	0.47

▸	LIMK2	P53671	3/20	0.47

▸	CDC7	O00311	1/20	0.38

▸	DAPK3	O43293	1/20	0.38

▸	JAK2	O60674	1/20	0.38

▸	ROCK2	O75116	1/20	0.38

▸	PRKD3	O94806	1/20	0.38

▸	MAP4K4	O95819	1/20	0.38

▸	PAK4	O96013	1/20	0.38

▸	PIM1	P11309	1/20	0.38

▸	PRKACA	P17612	1/20	0.38

▸	CDK2	P24941	1/20	0.38

▸	FLT3	P36888	1/20	0.38

▸	CSNK1A1	P48729	1/20	0.38

▸	CLK2	P49760	1/20	0.38

▸	GSK3A	P49840	1/20	0.38

▸	GSK3B	P49841	1/20	0.38

▸	CDK7	P50613	1/20	0.38

▸	CDK9	P50750	1/20	0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL4405171	0.90	MAPK14 (0.49)	MAPK14LIMK1LIMK2CDK2
SCHEMBL1616846	0.89	MAPK14 (0.48)	MAPK14LIMK1LIMK2CDK2CCNT1
SCHEMBL4413272	0.86	MAPK14 (0.48)	MAPK14LIMK1LIMK2CDK2CDK9
SCHEMBL4413265	0.86	MAPK14 (0.48)	MAPK14LIMK1LIMK2CDK2CDK9
SCHEMBL1615972	0.81	MAPK14 (0.56)	MAPK14LIMK1LIMK2CCNT1
SCHEMBL1616563	0.79	MAPK14 (0.59)	MAPK14LIMK1LIMK2
SCHEMBL1617109	0.79	MAPK14 (0.51)	MAPK14LIMK1LIMK2
SCHEMBL6001599	0.78	MAPK14 (0.57)	MAPK14LIMK1LIMK2
SCHEMBL13593841	0.78	MAPK14 (0.78)	MAPK14LIMK1LIMK2
SCHEMBL1617242	0.78	MAPK14 (0.61)	MAPK14LIMK1LIMK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-7923556-B2	Phenyl-substituted pyrimidine compounds useful as kinase inhibitors	BRISTOL-MYERS SQUIBB COMPANY (US)	2011-04-12	—	—	US	disclosed
US-7923556-B2	Phenyl-substituted pyrimidine compounds useful as kinase inhibitors	BRISTOL-MYERS SQUIBB COMPANY (US)	2011-04-12	—	—	US	disclosed
US-7923556-B2	Phenyl-substituted pyrimidine compounds useful as kinase inhibitors	BRISTOL-MYERS SQUIBB COMPANY (US)	2011-04-12	—	—	US	disclosed
US-20100029649-A1	PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS	BRISTOL-MYERS SQUIBB COMPANY	2010-02-04	—	—	US	disclosed
US-20100029649-A1	PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS	BRISTOL-MYERS SQUIBB COMPANY	2010-02-04	—	—	US	disclosed
US-20100029649-A1	PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS	BRISTOL-MYERS SQUIBB COMPANY	2010-02-04	—	—	US	disclosed
EP-1848714-B1	PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS	BRISTOL MYERS SQUIBB CO (US)	2009-12-30	—	—	EP	disclosed
US-20060178388-A1	Phenyl-substituted pyrimidine compounds useful as kinase inhibitors	BRISTOL-MYERS SQUIBB COMPANY	2006-08-10	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20100029649-A1	PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS	LIMK1, LIMK2, MAPK1	MAPK14 83/4885LIMK1 1/4885LIMK2 2/4885
US-20060178388-A1	Phenyl-substituted pyrimidine compounds useful as kinase inhibitors	LIMK1, LIMK2, MAPK1	MAPK14 83/4885LIMK1 1/4885LIMK2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.